AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas

Aurora B kinase inhibition in mitosis: Strategies for optimizing the use of Aurora kinase inhibitors such as AT9283

(2011) Jayne Curry et al.   CELL CYCLE

The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents

(2011) Deborah R. Wysong et al.   CELL CYCLE

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells

(2010) R. Tanaka et al.   BLOOD

Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?

(2010) A. A. Dar et al.   MOLECULAR CANCER THERAPEUTICS

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

(2010) T. Shimomura et al.   MOLECULAR CANCER THERAPEUTICS

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

(2009) Christopher D Scharer et al.   Journal of Translational Medicine

Analysis of Aurora B kinase in non-Hodgkin lymphoma

(2009) Takayuki Ikezoe et al.   LABORATORY INVESTIGATION

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model

(2009) E. C. VanderPorten et al.   MOLECULAR CANCER THERAPEUTICS

Cell cycle kinases as therapeutic targets for cancer

(2009) Silvia Lapenna et al.   NATURE REVIEWS DRUG DISCOVERY

Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma

(2008) Abhijit Mazumdar et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†

(2008) Steven Howard et al.   JOURNAL OF MEDICINAL CHEMISTRY